MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/jcm15010399

Медицинская библиотека · Journal of clinical medicine · 2026

Maternal-Fetal Implications of Mpox Infection: Current Evidence.

Pereira Stefany Silva, Braga Antonio, Rosolen Beatriz Bussi, Durães Talita Almeida, de Vita Silva Marcela Fermoselle, de Britto Giovanna Alves, Sales Giuliana Augustinelli, Callado Gustavo Yano, Maia Camilla Martins Dos Santos, Traina Evelyn, Araujo Júnior Edward, Tonni Gabriele, Granese Roberta

СтатьяОбзорПеревод в очереди

Аннотация

Mpox is an emerging zoonotic infection caused by the Monkeypox virus, an Orthopoxvirus with increasing global relevance following the 2022 multinational outbreak. Historically endemic to Central and West Africa, the disease has evolved from sporadic zoonotic transmission to sustained human-to-human spread, particularly through close physical and intimate contact. Clinical manifestations typically include fever, lymphadenopathy, and progressive mucocutaneous lesions, although severity varies according to viral clade, immune status, and comorbidities. The 2022 outbreak, predominantly associated with the Clade IIb variant, was characterized by milder disease, localized lesions, and reduced mortality compared with the more virulent Clade I variant. Despite this, severe outcomes remain possible, particularly in vulnerable groups such as children, pregnant individuals, immunocompromised patients, and persons with extensive dermatological disorders. Diagnosis relies primarily on polymerase chain reaction testing from lesion-derived samples, with genomic sequencing serving as a complementary tool for epidemiological surveillance. Management is largely supportive, though antivirals such as tecovirimat may be considered in severe cases or in high-risk populations. Data regarding therapeutic safety in pregnancy are limited; however, tecovirimat appears to have the most favorable profile, whereas cidofovir and brincidofovir remain contraindicated. Prevention strategies include targeted vaccination with the non-replicating Modified Vaccinia Ankara-Bavarian Nordic vaccine, used for both pre- and post-exposure prophylaxis, particularly in individuals at elevated risk. Given the evolving epidemiological profile, the potential for vertical transmission, and the risk of adverse perinatal outcomes, Mpox infection during pregnancy poses unique clinical challenges. This review synthesizes current evidence on virology, clinical presentation, diagnosis, prevention, and management, with an emphasis on obstetric considerations and public health implications.

Для цитирования: Pereira Stefany Silva, Braga Antonio, Rosolen Beatriz Bussi, Durães Talita Almeida, de Vita Silva Marcela Fermoselle, de Britto Giovanna Alves, Sales Giuliana Augustinelli, Callado Gustavo Yano, Maia Camilla Martins Dos Santos, Traina Evelyn, Araujo Júnior Edward, Tonni Gabriele, Granese Roberta. Maternal-Fetal Implications of Mpox Infection: Current Evidence.. Journal of clinical medicine. 2026. DOI: 10.3390/jcm15010399.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.